No results for ‘’
Camlin Fine Sciences Ltd
₹122.54
(1.10%)
Wed, 27 May 2026, 06:47 pm
Process Industries
Chemicals: Specialty
24.5KCamlin Fine Sciences EV/EBITDA Ratio
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 7.54 | 43.69 | 8.60 | 27.66 | 4.83 | 6.29 | 15.36 | 23.85 | 0 | 0 | 1050 | 15.77 | 37.95 | 30.62 | 41.42 | 0 | 0 |
| Price to book ratio | 0 | 0 | 0.63 | 1.80 | 1.36 | 1.98 | 1.11 | 1.94 | 6.28 | 4.85 | 4.36 | 3.33 | 1.63 | 1.19 | 2.77 | 2.93 | 2.44 | 1.73 | 3.50 |
| Price to sales ratio | 0 | 0 | 0.18 | 0.38 | 0.36 | 0.31 | 0.19 | 0.36 | 1.52 | 1.77 | 1.72 | 1.57 | 0.68 | 0.46 | 1.64 | 1.32 | 1.28 | 1.04 | 1.75 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 1.90 | 48.87 | 36.27 | 17.57 | 0 | 0 | 0 | 9.66 | 27.45 | 15.26 | 0 | 22.37 | 0 |
| Enterprise value | 0 | 0 | 451.52M | 960.84M | 1.16B | 2.2B | 1.73B | 3.15B | 9.86B | 10.16B | 12.14B | 13.99B | 10.18B | 10.09B | 24.16B | 23.78B | 28.64B | 20.9B | 33.7B |
| Enterprise value to EBITDA ratio | 0 | 0 | 2.64 | 7.63 | 10.12 | 7.28 | 3.62 | 4.87 | 11.52 | 11.53 | 29.73 | 102.55 | 15.56 | 7.98 | 12.34 | 15.30 | 13.11 | 11.07 | 15.81 |
| Debt to equity ratio | 1.04 | 0.76 | 0.97 | 1.60 | 1.47 | 2.36 | 1.92 | 1.61 | 1.19 | 1.02 | 1.56 | 1 | 1.24 | 1.34 | 0.85 | 0.86 | 0.98 | 0.79 | 0.76 |
| Return on equity % | 0 | 10.92 | 8.59 | 4.16 | 18.81 | 7.63 | 25.52 | 36.19 | 48.23 | 23.03 | -6.57 | -11.60 | 0.16 | 7.83 | 9.74 | 8.72 | 6.65 | 7.73 | 7.75 |
Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio
The Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Camlin Fine Sciences Ltd's valuation, profitability, and overall financial performance. Tracking the Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Camlin Fine Sciences Ltd (NSE: CAMLINFINE, BSE: 532834) is currently trading at ₹122.54, with a market capitalization of ₹23.31B. As a leading company in the Process industries sector and Chemicals: specialty industry, monitoring the Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio Current Value
The current Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio stands at 15.81.
The latest Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 15.81
- 2023: 11.07
- 2022: 13.11
- 2021: 15.30
- 2020: 12.34
The recent rise in Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio suggests strengthening valuation trends and improving market sentiment.
What Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Camlin Fine Sciences Ltd.
Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Camlin Fine Sciences Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.